

West Virginia Medicaid Drug Utilization Review Board Minutes November 17, 2021

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

K.C. Lovin, PA-C, Chair
Christopher Terpening, PharmD, PhD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
David Gloss, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

none

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Data Analyst
Gail Goodnight, RPh, Rebate Manager

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Rob Stanton, PharmD, MBA, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, Gainwell
Ryan Fell, PharmD, Change Healthcare

I. INTRODUCTIONS

- a. Chris Terpening, Vice Chair, welcomed everyone to the Board meeting at 4:05 pm EDT. The DUR Board introduced themselves.

II. APPROVAL OF MINUTES FROM September 22, 2021 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. **OLD BUSINESS**

none

IV. **NEW BUSINESS**

a. **Speakers**

- i. None, public comments were posted and representatives for agents on the agenda were available to sign up for questions from the board if necessary.

b. **Updates from October 27, 2021 P & T Committee Meeting**

- i. Ryan Fell presented the updates from the October 27, 2021 P & T meeting

c. **Prior Authorization Criteria. Attachment A**

- i. **Myfembree**: approved as presented

- ii. **MABS, ANTI-IL/IgE**: criteria approved as presented

1. **Dupixent**: approved as presented

2. **Fasenra**: approved as presented

3. **Xolair**: approved as presented

4. **Nucala**: approved as presented

- iii. **Cytokine/CAM antagonists**: criteria approved as presented

1. **Taltz**: approved as presented

- iv. **Hypoglycemia treatments- Baqsimi, Zegalogue**: approved as presented

v. **Aemcolo**: approved as presented

vi. **Epidiolex**: approved as presented

vii. **Rezurock**: approved as presented

viii. **Ozobax**: approved as presented

V. **REPORTS –3rd Quarter 2021**

- a. **Gainwell Technologies Quarterly Report**: Mr. Sears presented an overview of the 2021 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.

- b. **Rational Drug Therapy Program**: Dr. Wowczuk presented a review of the prior authorization program for the Third Quarter of 2021. Attachment C

- c. **Marshall University Coalition**: Dr. Stanton reported on the progress of retro DUR, the lock in program, DUR Medicaid survey findings, and number of letters sent/returned. attachment D

VI. **OTHER BUSINESS**

KC Lovin shared that she has been called to provide a deposition for the State of WV vs. Jansen Pharmaceuticals because she chairs the DUR Board.

New Chair for 2022. Email nominations to Doug Sorvig by 12-1-2021, expect to receive a ballot shortly after, vote by 12-15-2021.

VII. **NEXT MEETING AND ADJOURNMENT**

VIII.

IX.

- a. The meeting concluded at 5:29 pm EDT.

- b. The next meeting will be in February. Meeting dates/times to come out soon for 2022.